Comparison of Buprenorphine and Methadone - 3

This study has been completed.
Washington D.C. Veterans Affairs Medical Center
Information provided by:
National Institute on Drug Abuse (NIDA) Identifier:
First received: September 20, 1999
Last updated: June 2, 2015
Last verified: December 2002
The purpose of this study is to compare agonist and antagonist profile associated with buprenorphine vs. methadone during opiate withdrawal.

Condition Intervention Phase
Opioid-Related Disorders
Drug: Buprenorphine
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Pharmacological Comparison of Buprenorphine and Methadone

Resource links provided by NLM:

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Withdrawal severity
  • Opiate agonist symptoms

Estimated Enrollment: 0

Ages Eligible for Study:   23 Years to 45 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Please contact site for information.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00000334

United States, District of Columbia
Washington DC VA
Washington, District of Columbia, United States, 20422
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
Washington D.C. Veterans Affairs Medical Center
Principal Investigator: Steven Deutsch, M.D. Washington D.C. Veterans Affairs Medical Center
  More Information

No publications provided Identifier: NCT00000334     History of Changes
Other Study ID Numbers: NIDA-3-0009-3, Y01-3-0009-3
Study First Received: September 20, 1999
Last Updated: June 2, 2015
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Opioid-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Substance-Related Disorders
Analgesics, Opioid
Central Nervous System Agents
Central Nervous System Depressants
Narcotic Antagonists
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses processed this record on November 30, 2015